- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Therapeutic modulation of E3 ubiquitin ligase activity
Benjamin L. Ebert
Dana-Farber Cancer Institute, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Navigating gene-gene and drug-gene interaction landscapes underpinning the DNA damage response
Daniel Durocher
Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada
- Free
- slides video
- audio + slides
- All slides included
Background and use of circulating tumor-derived DNA and circulating tumor cells as biomarkers
Martijn Lolkema
Erasmus MC, Rotterdam, Netherlands
- Free
- slides video
- audio + slides
- All slides included
The KRASG12C inhibitor, MRTX849, provides insight toward therapeutic susceptibility of KRAS mutant cancers
James G Christensen
Mirati Therapeutics, San Diego, CA, United States
- Free
- slides video
- audio + slides
- All slides included
A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRASG12C inhibitor, in advanced solid tumors
Pasi A Jänne
Dana-Farber Cancer Institute, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
The dark side of immunotherapy
Emiliano Calvo
Start Madrid, Madrid, Spain
- Free
- slides video
- audio + slides
- All slides included
Inhibitors of the HSF1 stress pathway derived from phenotypic screening: Targeting non-oncogene addiction in ovarian and other cancers
Paul Workman
The Institute of Cancer Research, London, United Kingdom
- Free
- podium video
- audio + slides
- Some slides withheld
Early lessons from initial acquired resistance to TRK inhibitors
David M Hyman
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- audio + slides
- All slides included
From big data to smart data: Overcoming biomedical reductionism
Sean Khozin
U.S. Food & Drug Administration, Silver Spring, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Identifying novel immunotherapy strategies using human samples and pre-clinical models
Jennifer L Guerriero
Dana-Farber Cancer Institute, Boston, MA, United States
- Free
- Coming soon
- Some slides withheld
Successes and failures of targeted drug development in adult and pediatric sarcomas
Jaap Verweij
Erasmus University Medical Center, Rotterdam, Netherlands
- Free
- audio + slides
- Some slides withheld
Successes and failures of targeted drug development in pediatric tumors
Elizabeth Fox
Children’s Hospital of Pennsylvania, Philadelphia, PA, United States
- Free
- slides video
- audio + slides
- All slides included
Targeted therapy with protein kinase inhibitors: Lessons learned from the last 20 years
Michael C Heinrich
Oregon Health and Science University, Portland, OR, United States
- Free
- podium video
- audio only
- Audio only
Dissecting antitumor immune response in ovarian cancer
George Coukos
University of Lausanne, Lausanne, Switzerland, Lausanne, Switzerland
- Permission not
granted for presentation
New CAR T cells on the horizon
Marcela V Maus
Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
- Permission not
granted for presentation
New targets and technologies for CAR-T
Michael Hudecek
University Hospital Wurzburg, Wurzburg, Germany
- Free
- podium video
- audio only
- Audio only
Engineering CAR T Cells to Overcome Resistance
Crystal L Mackall
Stanford University School of Medicine, Stanford, California, Stanford, CA, United States
- Free
- podium video
- audio only
- Audio only
Targeted Protein Degradation as a new Approach to Cancer Drugs
Nathanael S Gray
Dana-Farber Cancer Institute, Boston, MA, United States
- Free
- podium video
- audio + slides
- Some slides withheld
Exploiting E3 ligases for target validation and drug discovery: What have we learnt so far?
Rajesh Chopra
The Institute of Cancer Research, London, United Kingdom
- Free
- Coming soon
- Some slides withheld
The zinc-finger degrome
Nicolas H. Thoma
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
- Free
- slides video
- audio + slides
- All slides included
A phase I study targeting the APE1/Ref-1 DNA repair-redox signaling protein with the APX3330 inhibitor
Mark R. Kelley
Indiana University School of Medicine, Indianapolis, IN, United States
- Free
- slides video
- audio + slides
- All slides included
Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
Alison M Schram
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion
Rebecca S Heist
Massachusetts General Hospital, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
CAR-T and directed T-cell therapy: Where are we right now?
Victor Moreno
START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain
- Permission not
granted for presentation
T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers
Smita Chandran
Memorial Sloan Kettering Cancer Center, New York, NY, United States